PHILADELPHIA, Aug. 26, 2020 /PRNewswire/ — Tridiuum, the nation’s premier provider of digital behavioral health solutions, today released the results of a new survey about the current and future state of telemental healthcare delivery. The survey found that 81 percent of behavioral health providers began using telehealth for the first time in the last six months due to the COVID-19 pandemic. Even more importantly, 70 percent of respondents reported they plan to continue offering telehealth services post-pandemic, and that they intend to leverage video visits for at least 50 percent of their patients moving forward.
The findings are significant because behavioral health providers have historically cited concerns that virtual therapy could not be as effective as in-person visits – despite the volume of literature that has proven those fears are unwarranted. As a result, behavioral health providers lagged even further behind primary care and other physical health providers in adoption of telehealth prior to the pandemic. The new Tridiuum survey, based on feedback from 438 mostly first-time users, is real-world confirmation that behavioral healthcare delivered via video-conferencing is comparable or even better on multiple quality indicators.
The survey’s top insights regarding the impact on clinical care include:
“At Tridiuum, we are always eager to innovate and adapt to help behavioral health providers and the patients they serve,” said Mark Redlus, CEO for Tridiuum. “These survey results are yet another data point to illustrate that telemental healthcare is not less effective than in-person care. In fact, it can even improve clinical care, while offering providers and patients the options they need, want, and deserve. As the industry continues to shift toward virtual care, we’re proud to partner with so many independent and group behavioral providers to support their telemental health efforts, improve outcomes, and to do our part to make a difference in patients’ lives.”
Tridiuum first announced the addition of HIPAA-compliant video capabilities to its Tridiuum ONE platform to enhance telemental health sessions in April. Tridiuum’s platform also facilitates measurement-based care (MBC), which has strong empirical support for improving patient engagement and outcomes. Tridiuum ONE equips providers with the tools needed to accurately measure patient progress, identify when there’s a need to alter treatment course, and identify patients who may be ready to graduate from care.
To learn more about Tridiuum’s telemental health survey, register now to receive the comprehensive white paper results when they are available in September.
About Tridiuum
Tridiuum, the premier provider of digital behavioral health solutions, is accelerating improved outcomes and reduced costs by reimagining how behavioral healthcare is delivered. The company’s flagship platform, Tridiuum ONE, combines nearly 20 years of behavioral health research and clinical expertise with cutting-edge technology to power behavioral health operations and workflows in a way that advances patient outcomes. It is proven to identify behavioral conditions faster, accelerate access to care, engage patients, and deliver vital treatment progress tracking. The scalable technology also integrates seamlessly with most electronic health records and health IT software. Almost 2,000 clinical facilities use the Tridiuum ONE platform, with more than 6,500 behavioral health providers using it to advance treatment for more than 11,000 patients every day. To learn more, visit https://tridiuum.com.
Media Contact:
Lisa Chernikoff
Canton & Company for Tridiuum
246189@email4pr.com
734.678.5513
View original content:http://www.prnewswire.com/news-releases/telemental-health-survey-reveals-70-percent-of-behavioral-health-providers-will-continue-offering-telehealth-options-post-covid-19-301118459.html
SOURCE Tridiuum
NEW YORK, July 4, 2024 /PRNewswire/ -- The global breast tissue expander market size is estimated to…
CHICAGO, July 4, 2024 /PRNewswire/ -- The global microscopy market is poised for significant growth, expected…
Toronto, Ontario--(Newsfile Corp. - July 4, 2024) - FSD Pharma Inc. (NASDAQ: HUGE) (CSE: HUGE)…
MARBURG, Germany, July 04, 2024 (GLOBE NEWSWIRE) -- Global biotechnology leader CSL Behring (ASX: CSL)…
SKYSCRAPER-06 evaluating tiragolumab plus Tecentriq and chemotherapy did not meet the primary endpoints of progression-free…
ICPO Center NuMeRI ICPO Foundation signed the contract with Nuclear Medicine Research Infrastructure (NuMeRI) to…